BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 15 APRIL 2010 at 1 p.m. RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. The Annual General Meeting of Biotie Therapies Corp. was held on 15 April 2010. Adoption of financial statements for the financial year 1 January - 31 December 2009 and booking of the loss of the financial year The General Meeting of Shareholders adopted the financial statements for the financial year 1 January - 31 December 2009. The General Meeting resolved in accordance with the proposal of the Board of Directors that the loss of the financial year shall be transferred to the unrestricted equity and no dividend shall be paid. The General Meeting discharged the members of the Board of Directors and the President and CEO from liability concerning the financial year from 1 January - 31 December 2009. The Board of Directors and auditors The number of the members of the Board of Directors was resolved to be seven. Peter Fellner, Merja Karhapää, Bernd Kastler, Pauli Marttila, Riku Rautsola, Pierre Serrure and James S. Shannon were elected as the members of the Board of Directors. The General Meeting resolved that the remuneration payable to the Chairman of the Board of Directors be EUR 4,000 per month and to other Board members EUR 3,000 per month. In addition, reasonable travelling expenses for the meetings shall be compensated. PricewaterhouseCoopers Oy, a firm of auditors approved by the Central Chamber of Commerce, and Janne Rajalahti, Authorized Public Accountant, were re-elected as auditors of the company. At the organization meeting of the new Board of Directors, which convened immediately after the Annual General Meeting, Peter Fellner was elected as the Chairman of the Board of Directors and Pauli Marttila as the deputy chairman. Bernd Kastler was elected as the Chairman and Merja Karhapää, Riku Rautsola and Pierre Serrure as the members of the Board's Audit Committee and in addition Peter Fellner as the Chairman and Pauli Marttila and James S. Shannon as the members of the Nomination and Remuneration Committee. Based on the evaluation of independence, the Board concluded that all Board members are independent of the company and of its significant shareholders. Authorisation of the Board of Directors to decide on the issuance of shares as well as the issuance of options and other rights entitling to shares The General Meeting authorised the Board of Directors to resolve on one or more issues which contains the right to issue new shares or dispose of the shares in the possession of the company and to issue options or other rights to the shares pursuant to chapter 10 of the Companies Act. The authorisation consists of up to 80,000,000 shares in aggregate. The authorisation does not exclude the Board of Directors' right to decide on a directed issue. The authorisation may be used for material arrangements from the company's point of view, such as financing or implementing business arrangements or investments or for other such purposes determined by the Board of Directors in which case a weighty financial reason for issuing shares, options or other rights and possibly directing a share issue would exists. The Board of Directors was authorised to resolve on all other terms and conditions of a share issue, options and other share entitlements as referred to in chapter 10 of the Companies Act, including the payment period, determination grounds for the subscription price and subscription price or allocation of shares, option or other rights free of charge or that the subscription price may be paid besides in cash also by other assets either partially or entirely. The authorisation is effective until 30 June 2011 and it supersedes earlier authorisations. President and CEO's review Timo Veromaa, President and CEO, discussed the company's operations, results and future in his review. The presentation is available on the company's website at www.biotie.com. The minutes of the meeting will be available on the company's website as from 29 April 2010. Turku, 15 April 2010 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Timo Veromaa, President and CEO, Biotie Therapies Corp. tel. +358 2 274 8901, e-mail:timo.veromaa@biotie.com <mailto:timo.veromaa@biotie.com> www.biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media [HUG#1403981]